GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk

Dow Jones05-06

1335 GMT - GSK's drug pipeline is moving in the right direction, but the U.K. drugmaker might need to do more to counter the effect of looming patent expirations, Citi analysts say. The company plans to give an update on its broader pipeline when it reports second-quarter results, instead of an event focused on its HIV franchise in June as previously expected. The change makes sense in light of recent activity on the pipeline, with ten pivotal trial starts, five key study-data releases and two acquisitions, the analysts say. That said, the steps GSK has taken so far aren't enough to counter its large patent expirations, they add. Citi lowers its target price on GSK stock to 21 pounds from 22.50 pounds. Shares rise 1.3% to 18.81 pounds.(adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 06, 2026 09:35 ET (13:35 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633513933?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633513933","market":"sh","top_or_hot":-1,"title":"GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1335 GMT - GSK's drug pipeline is moving in the right direction, but the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker might need to do more to counter the effect of looming patent expirations, Citi analysts say. The company plans to give an update on its broader pipeline when it reports second-quarter results, instead of an event focused on its HIV franchise in June as previously expected. The change makes sense in light of recent activity on the pipeline, with ten pivotal trial starts, five key study-data releases and two acquisitions, the analysts say. That said, the steps GSK has taken so far aren't enough to counter its large patent expirations, they add. Citi lowers its target price on GSK stock to 21 pounds from 22.50 pounds. Shares rise 1.3% to 18.81 pounds.(adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2026 09:35 ET (13:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-06 21:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1335 GMT - GSK's drug pipeline is moving in the right direction, but the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker might need to do more to counter the effect of looming patent expirations, Citi analysts say. The company plans to give an update on its broader pipeline when it reports second-quarter results, instead of an event focused on its HIV franchise in June as previously expected. The change makes sense in light of recent activity on the pipeline, with ten pivotal trial starts, five key study-data releases and two acquisitions, the analysts say. That said, the steps GSK has taken so far aren't enough to counter its large patent expirations, they add. Citi lowers its target price on GSK stock to 21 pounds from 22.50 pounds. Shares rise 1.3% to 18.81 pounds.(adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2026 09:35 ET (13:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2633513933","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633513933","pubTimestamp":1778074500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1335 GMT - GSK's drug pipeline is moving in the right direction, but the U.K. drugmaker might need to do more to counter the effect of looming patent expirations, Citi analysts say. The company plans to give an update on its broader pipeline when it reports second-quarter results, instead of an event focused on its HIV franchise in June as previously expected. The change makes sense in light of recent activity on the pipeline, with ten pivotal trial starts, five key study-data releases and two acquisitions, the analysts say. That said, the steps GSK has taken so far aren't enough to counter its large patent expirations, they add. Citi lowers its target price on GSK stock to 21 pounds from 22.50 pounds. Shares rise 1.3% to 18.81 pounds.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"葛兰素史克正在朝着正确的方向采取措施，但可能需要更多——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.5},"content_text":"1335 GMT - GSK's drug pipeline is moving in the right direction, but the U.K. drugmaker might need to do more to counter the effect of looming patent expirations, Citi analysts say. The company plans to give an update on its broader pipeline when it reports second-quarter results, instead of an event focused on its HIV franchise in June as previously expected. The change makes sense in light of recent activity on the pipeline, with ten pivotal trial starts, five key study-data releases and two acquisitions, the analysts say. That said, the steps GSK has taken so far aren't enough to counter its large patent expirations, they add. Citi lowers its target price on GSK stock to 21 pounds from 22.50 pounds. Shares rise 1.3% to 18.81 pounds.(adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2026 09:35 ET (13:35 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633513933","isCrawlerRequest":true}